Table 5 Selective clinical trials of PARP inhibitors
From: Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Drug | Target | Condition | Status | Phase | NCT identifier |
|---|---|---|---|---|---|
Olaparib (AZD2281) | PARPs | PCa | Completed | 1 | NCT02324998 |
Olaparib (AZD2281) | PARPs | mCRPC | Not yet recruiting | 3 | NCT03732820 |
Olaparib (AZD2281) | PARPs | mCRPC | Not yet recruiting | 3 | NCT02987543 |
Olaparib (AZD2281) | PARPs | mCRPC | Not yet recruiting | 3 | NCT03834519 |
Rucaparib (AG014699) | PARPs | HR deficient mCRPC | Completed | 2 | NCT02952534 |
Rucaparib (AG014699) | PARPs | mCRPC | Not yet recruiting | 3 | NCT02975934 |
Veliparib (ABT-888) | PARPs | mCRPC | Completed | 2 | NCT01576172 |
Talazoparib (BMN 673) | PARPs | HR deficient mCRPC | Not yet recruiting | 2 | NCT03148795 |
Talazoparib (BMN 673) | PARPs | mCRPC | Recruiting | 3 | NCT03395197 |
Niraparib (MK-4827) | PARP1/2 | mCRPC | Completed | 1 | NCT02924766 |
Niraparib (MK-4827) | PARP1/2 | mCRPC | Recruiting | 3 | NCT04497844 |
Pamiparib (BGB-290) | PARP1/2 | mCRPC | Terminated | 2 | NCT03712930 |
Pamiparib (BGB-290) | PARP1/2 | mCRPC | Not yet recruiting | 1 | NCT03150810 |
